Hepatic veno-occlusive disease associated with immunosuppressive cyclophosphamide dosing and roxithromycin.

Article Details

Citation

Copy to clipboard

Beltinger J, Haschke M, Kaufmann P, Michot M, Terracciano L, Krahenbuhl S

Hepatic veno-occlusive disease associated with immunosuppressive cyclophosphamide dosing and roxithromycin.

Ann Pharmacother. 2006 Apr;40(4):767-70. Epub 2006 Mar 7.

PubMed ID

16595573 [ View in PubMed

]

Abstract

OBJECTIVE: To report on a patient developing hepatic veno-occlusive disease while being treated with immunosuppressive doses of cyclophosphamide (< or =2 mg/kg). CASE SUMMARY: A 66-year-old woman with autoimmune hemolytic anemia developed hepatic veno-occlusive disease while being treated with immunosuppressive cyclophosphamide 100 mg/day in combination with roxithromycin (total dose 600 mg/day). After all drugs were stopped, the patient recovered within 2 weeks. The Naranjo probability scale indicated a probable relationship between veno-occlusive disease and treatment with cyclophosphamide in this patient. DISCUSSION: Since roxithromycin inhibits CYP3A4, which is involved with cyclophosphamide metabolism, a drug-drug interaction could have been responsible. In addition, roxithromycin is an inhibitor of the drug transporter P-glycoprotein, possibly leading to accumulation of cyclophosphamide in endothelial cells. Alternatively, since cyclophosphamide has been reported to induce apoptosis, roxithromycin could have rendered endothelial cells more vulnerable for apoptosis. CONCLUSIONS: In specific patients, cyclophosphamide can be associated with hepatic veno-occlusive disease at immunosuppressive doses.

DrugBank Data that Cites this Article

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Roxithromycin	P-glycoprotein 1	Protein	Humans	Unknown	Not Available	Details